 Research published in the journal "Cancer" on 15 May 2006 reports evidence that actibind has antiangiogenic and anticarcinogenic characteristics.In human colon cancer, breast cancer and melanoma, increasing the level of actibind was found to reduce the ability of these cells to form tumorogenic colonies.In animal models, increased actibind inhibited the growth of colon cancer-derived tumors, metastases and blood vessel formation.